Sequenom Shares Fall on Potential Competition; Analyst Says Sell-off Is Unwarranted | GenomeWeb
NEW YORK (GenomeWeb News) – Shares of Sequenom closed down 12.3 percent in late Tuesday afternoon trade after the release of a paper by a noted Stanford researcher demonstrating a potentially competitive technology to the firm’s non-invasive test for Down syndrome.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: miR-515 levels higher in women with preeclampsia, horizontal gene transfer in parasitic plants, and more.

A cancer researcher retracts 19 articles from one journal for image manipulation, according to Retraction Watch.

Precision medicine has to consider context in addition to genetic mutations in cancer treatment, Medscape reports.

Genomics may help the Cavendish banana from succumbing to fungal infections, a trio of researchers writes at the Conversation.